Top news of the week: 07.07.2021.
Startups
The 'dovetail' partnership meant to turn Boston Children's into a hub for gene therapy startups
A five-year alliance with high-profile biotech ElevateBio is designed to get around a bottleneck that has held back the institution’s gene therapy work.
Eschewing an IPO (for now), Sirnaomics nabs a rare series E worth $105M for next-gen RNA work
It’s a case of déjà vu (and no IPO) for the U.S.-China RNAi biotech Sirnaomics as it grabs a $105 million funding round, just under a year after grabbing the same amount in a D round.
Top 10 Synthetic Biology Companies
GEN’s first-ever A-List for synthetic biology ranks the five largest public companies by their 2020 revenues, and the five largest private companies by the total capital they have raised.
Goldman Sachs, EQT to Buy Parexel for $8.5B, Continuing CRO Consolidation
Parexel is being sold for $8.5 billion by Pamplona Capital to Swedish private equity firm EQT and the private equity business of Goldman Sachs Asset Management.
Elliott fires opening salvo at GlaxoSmithKline, calling for new management to fix 'severe underperformance'
After months of plotting in secret, Elliott Management has finally made its intentions around GlaxoSmithKline known. The activist investment group is calling for drastic changes at the ...
Member Spotlight: Q&A with Anika Therapeutics
In July, we spoke with Cheryl Blanchard, Ph.D., President and Chief Executive Officer, Anika Therapeutics, Inc.
Parexel snapped up, again, as Goldman Sachs, EQT spend $8.5B on the CRO
The rumors were true: Whispers grew this year that Parexel, owned for the past four years by Pamplona Capital, was seeking a sale or an IPO. Today, the whispers stopped as the CRO loudly ...
Pharma primed for LBO hot potato
Private equity firms are on the hunt. And with $1 trillion sloshing around , the industry is bound to start playing hot potato. That happened Friday, with buyout firm EQT and Goldman ...